StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Aggregate of 12 sell-side ratings as of 2026-05-01. Stonvex does not endorse these ratings.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-15 | $25.95 | $25.56 | -1.50% | 0.4M |
| 05-18 | $25.54 | $24.50 | -4.07% | 0.6M |
| 05-19 | $24.29 | $24.46 | +0.70% | 0.5M |
| 05-20 | $24.73 | $25.03 | +1.21% | 0.3M |
| 05-21 | $24.96 | $25.75 | +3.17% | 0.4M |
Earnings (▲ beat / ▼ miss) and ex-dividend dates plotted on the price line. Educational — proximity does not establish causation.
Next report date, year-over-year trend, and recent quarter history.
Aggregated from Polygon's per-article sentiment classifications. Educational — sentiment is descriptive, not predictive.
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
These are published opinions from external sell-side analysts — not Stonvex recommendations. Ratings may change without notice, may conflict with each other, and may be wrong. Not investment advice.
Consensus aggregated from publicly disclosed sell-side analyst ratings. Stonvex is not a registered investment advisor and does not endorse any of the ratings shown. Past analyst ratings do not predict future price movements.
Past 1 reported quarters: EPS surprise vs estimate and the day-after-release stock reaction. Past performance does not predict future moves.
Sources: Finnhub earnings calendar + Polygon daily aggregates. Reaction direction can diverge from EPS surprise (guidance, macro, or sector flow can dominate the next-day print).
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q3 2026 (Est.) Expected 2026-08-10 | Q1 2026 2026-03-31 | Q2 2025 2025-06-30 | Annual 2024 2024-12-31 | Q3 2024 2024-09-30 |
|---|---|---|---|---|---|
Revenue | $566.67K | $20.00M | $0.00 | $167.50M | $167.50M |
Operating Income | Not available | $-26.55M | $-71.88M | $57.59M | $87.31M |
Net Income | Not available | $-24.21M | $-33.68M | $52.23M | $81.81M |
EPS (Diluted) | $-0.78 | $-0.45 | $-1.83 | $1.25 | $2.67 |
Total Assets | Not available | $419.71M | $303.52M | $240.54M | Not available |
Total Liabilities | Not available | $78.01M | $41.28M | $43.64M | Not available |
Cash & Equivalents | Not available | $198.77M | $264.54M | $196.81M | $149.61M |
Free Cash Flow OCF − CapEx | Not available | $-39.21M | $-60.26M | $74.81M | $97.86M |
Shares Outstanding | Not available | 49.74M | 43.85M | 2.45M | 3.39M |
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular, and related metabolic, or CVRM, diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows the company to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD.
MAZE is in the extended universe. We surface dollar-volume + price-change percentiles for every US-listed name, but the full 6-factor DNA breakdown (momentum, news, sentiment, flow, relative strength) is only computed on the curated 1137-name primary list.
DNA analysis is not available for this ticker.
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.